Global Wildlife Health Market to Reach $4.5 Billion by 2030 at 10.7% CAGR

April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Biologic & Biosimilar RA Drugs Market Projected To Become By 2030 Based On Its 2026 Valuation?

The wildlife health market has seen considerable growth recently. Its valuation is anticipated to climb from $2.74 billion in 2025 to $3.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.0%. This historical expansion is attributable to several factors, including an increase in wildlife diseases, the proliferation of zoos and wildlife sanctuaries, extended veterinary treatments for mammals and birds, the innovation of specialized wildlife medicines, and a heightened understanding of conservation and animal welfare.

The wildlife health market is poised for significant expansion in the coming years, with projections indicating a rise to $4.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This anticipated growth is driven by several factors including progress in wildlife medicine and therapeutics, the implementation of digital monitoring and tracking technologies, enhanced government backing for wildlife health initiatives, a rise in ecotourism and conservation efforts, and the incorporation of precision medicine into wildlife healthcare. Key trends expected during this period involve a heightened emphasis on monitoring wildlife diseases, the uptake of specialized veterinary medications for wildlife, an increase in wildlife rescue and rehabilitation activities, a surging need for monitoring habitat health and conservation, and the application of injectable and oral treatments for a variety of species.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12183&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Biologic & Biosimilar RA Drugs Market?

The wildlife health market is anticipated to experience growth, primarily propelled by wildlife conservation measures and associated funding activities. These conservation measures encompass a wide array of strategies and actions designed to preserve and protect biodiversity, often requiring substantial financial support to facilitate habitat restoration, anti-poaching efforts, research initiatives, and community engagement for sustainable wildlife management. The wildlife health market plays a vital role in supporting these wildlife conservation measures and funding activities by providing essential services, diagnostics, and treatments that contribute to the overall well-being of wildlife populations, thereby reinforcing the foundations for sustainable conservation. For instance, in September 2023, the United States Department of the Interior, through the U.S. Fish and Wildlife Service, allocated over $40.6 million in grants, leveraging an additional $17.6 million, to 10 states and the U.S., specifically to enable the acquisition and protection of 7,200 acres of habitat and to support the implementation of state programs under the Endangered Species Act for the conservation and recovery of federally listed and at-risk species on non-federal lands. Thus, wildlife conservation measures and funding activities are driving the expansion of the wildlife health market.

What Segment Groups Are Identified Within The Biologic & Biosimilar RA Drugs Market?

The wildlife health market covered in this report is segmented –

1) By Animal Type: Mammals, Birds, Fish, Reptiles, Amphibians

2) By Product: Medicine, Equipment And Consumables

3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

4) By End-User: Zoos, Wildlife Sanctuaries, Wildlife Rescue And Rehab Centers, Other End Users

Subsegments:

1) By Mammals: Large Mammals, Small Mammals

2) By Birds: Raptors, Waterfowl, Songbirds

3) By Fish: Freshwater Fish, Saltwater Fish

4) By Reptiles: Snakes, Lizards, Turtles And Tortoises

5) By Amphibians: Frogs, Salamanders, Newts

What Trends Are Advancing Progress In The Wildlife Health Market?

Leading entities within the wildlife health market are incorporating innovative technologies to sustain their market standing. These technological advancements encompass sophisticated diagnostic instruments, therapeutic approaches, and surveillance mechanisms aimed at enhancing wildlife health administration and preventing diseases. For instance, in February 2023, the U.S. Department of Agriculture (USDA), a US-based federal agency, introduced novel tests to monitor and identify COVID variants in both wild and domesticated animals. Such tools are instrumental in controlling the propagation of zoonotic diseases. Presently, the USDA Animal and Plant Health Inspection Service (APHIS) is utilizing a $300 million allocation from the American Rescue Plan Act to carry out monitoring and surveillance activities for the COVID virus in susceptible animal populations. As part of this endeavor, ARS, collaborating with APHIS, is undertaking five research initiatives aimed at deepening its comprehension of the virus and assisting APHIS in achieving its objective of establishing an early warning system to potentially avert or mitigate future zoonotic disease outbreaks or global pandemics.

Which Companies Hold Significant Positions In The Biologic & Biosimilar RA Drugs Market?

Major companies operating in the wildlife health market are Bayer AG, Novartis AG, Merck & Co Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, IDEXX Laboratories Inc., Génia USA Inc., Orion Corporation, Virbac Group, Royal Canin, Ceva Santé Animale Group, Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Huvepharma, Vétoquinol, Indian Immunologicals Limited, Norbrook Laboratories Limited, Heska Corporation, Biogenesis Bago, Animalcare Group plc, Pneu-Dart Inc., PetAg Inc.

Read the full wildlife health market report here:

https://www.thebusinessresearchcompany.com/report/wildlife-health-global-market-report

Which Regions Are Projected To Dominate The Biologic & Biosimilar RA Drugs Market In The Coming Years?

North America was the largest region in the wildlife health market in 2025. The regions covered in the wildlife health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologic & Biosimilar RA Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12183&type=smp

Browse Through More Reports Similar to the Global Wildlife Health Market 2026, By The Business Research Company

Animal Health Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/animal-health-global-market-report

Environment Conservation And Wildlife Organizations Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/environment-conservation-and-wildlife-organizations-global-market-report

Farm Animal Healthcare Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/farm-animal-healthcare-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795